—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from prior 2027 net cash gu

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties, and may opt-in to 50/50 development and profit share of KT-485 in the U.S. June 25, 2025 -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stag

June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis. “We are pleased to complete this transaction and take the next step in advancing clinical development for a potential first-in-

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University June 25, 2025 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metab

June 24, 2025 -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction (DDI) studies, to certify impurities are

Combination cohort initiated following successful review of monotherapy cohort Over 100 participants dosed to-date in monotherapy cohort Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer Data update on schedule for later this year June 25, 2025 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of

June 17, 2025 -- This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today congratulates its strategic partner and largest shareholder, Juvenescence Ltd., on the $76 million first tranche close of its targeted $150 million Series B financing, as well as its new strategic partnership with M42,

June 11, 2025 -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with stero

June 04, 2025 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. (“Cook MyoSite”) to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-F

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvak